ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) has provided an announcement.
ImmuneOnco Biopharmaceuticals has announced amendments to its Articles of Association following a recent increase in its share capital. The company’s total issued shares have risen due to the completion of a new H shares placing, reflecting a strategic move to enhance its financial position and support future growth initiatives.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, specializing in immunotherapy treatments. The company focuses on developing innovative cancer treatments and is listed on the Hong Kong Stock Exchange under the stock code 1541.
YTD Price Performance: -4.84%
Average Trading Volume: 12,322,773
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$2B
For a thorough assessment of 1541 stock, go to TipRanks’ Stock Analysis page.